Developmental Program Abstract Our Developmental Program strategy will include both the Pilot Projects and Auxiliary Projects. These programs facilitate seeding new ideas and efforts for which no direct funding mechanism exists since not enough preliminary data has been accumulated or needs an incentive to bring scientists with diverse skill sets to address a difficult question. This has been a highly successful program in previous phases, and has resulted in a large number of publications and further funding opportunities. We will expand the Pilot Program by allocating $100,000 per year of CCNE funds. This allocation will again be matched dollar for dollar through a commitment we negotiated from the CINM and LCCC (Letter of Support in Overall Section 1). This collaboration will result in a total of $200,000 per year to support four $50,000 per year Pilot Projects. In Auxiliary Projects, is designed to foster collaborations between various Nano Alliance members and other institutions to provide additional scientific expertise that benefits both groups. For C- CCNE Phase 3, $50,000 annually has been dedicated for Auxiliary Projects. This ties in extremely well with UNC's goals of supporting research intended to encourage collaboration of investigators from different disciplines, institutions and communities that result in transformative approaches to healthcare issues.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-TCRB-Q (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Myung, Ja Hye; Eblan, Michael J; Caster, Joseph M et al. (2018) Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture. Clin Cancer Res 24:2539-2547
Liu, Qi; Zhu, Hongda; Tiruthani, Karthik et al. (2018) Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma. ACS Nano 12:1250-1261
Song, Wantong; Shen, Limei; Wang, Ying et al. (2018) Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat Commun 9:2237
Hou, Lin; Liu, Qi; Shen, Limei et al. (2018) Nano-delivery of fraxinellone remodels tumor microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma. Theranostics 8:3781-3796
Liu, Qi; Zhu, Hongda; Liu, Yun et al. (2018) BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma. Cancer Immunol Immunother 67:299-310
Mi, Yu; Smith, Christof C; Yang, Feifei et al. (2018) A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy. Adv Mater 30:e1706098
Zhou, Jingying; Liu, Man; Sun, Hanyong et al. (2018) Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut 67:931-944
Wan, Xiaomeng; Beaudoin, James J; Vinod, Natasha et al. (2018) Co-delivery of paclitaxel and cisplatin in poly(2-oxazoline) polymeric micelles: Implications for drug loading, release, pharmacokinetics and outcome of ovarian and breast cancer treatments. Biomaterials 192:1-14
Collier, Michael A; Junkins, Robert D; Gallovic, Matthew D et al. (2018) Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists. Mol Pharm 15:4933-4946
Liu, Lina; Wang, Yuhua; Miao, Lei et al. (2018) Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer. Mol Ther 26:45-55

Showing the most recent 10 out of 47 publications